Managing chronic discomfort in pets — whether from osteoarthritis, age-related stiffness, or ongoing inflammatory conditions — requires a thoughtful approach. Prescription NSAIDs are effective but carry GI and renal risks with long-term use, particularly in senior animals. For pet owners seeking a natural alternative or complementary option, the combination of Boswellia serrata and hemp-derived phytocannabinoids represents a novel and well-received approach that is now available in Canada in veterinary-authorized form.
Aventi Synergy Chewable Tablets from Aventix are registered with Health Canada as a Veterinary Health Product (NN. F3T1). This is notable: unlike many hemp-based pet products sold without regulatory oversight, Aventi Synergy has undergone the Health Canada VHP registration process, providing meaningful quality assurance. The formula is designed for both dogs and cats experiencing joint discomfort, age-related stiffness, or chronic health conditions affecting quality of life.
The core of the formula is a synergistic combination of two botanicals: Boswellia serrata extract (192 mg) delivered through the patented Casperome® phytosome technology, which significantly enhances oral absorption and bioavailability of boswellic acids — the active anti-inflammatory compounds. Boswellic acids specifically inhibit 5-LOX (5-lipoxygenase), an enzyme pathway responsible for leukotriene-mediated inflammation that glucosamine/chondroitin supplements do not address. The second component is dried hemp seed and hemp seed oil (Cannabis sativa, 138 mg), actively selected for naturally occurring phytocannabinoids and terpenes in compliance with Health Canada regulations. The formula also includes Superoxide Dismutase (SOD) for antioxidant protection and Arginine for circulation support.
The result is a supplement that addresses inflammation through multiple distinct pathways, supports cognitive function in aging pets, and provides visible relief — many owners report noticeable improvements within 2 weeks of starting.
Key Active Ingredients per Tablet:
Directions for Use:
Give based on body weight as directed on packaging. Can be given directly by mouth, or crushed and mixed with food. Do not remove from packaging until ready to use. When using a half tablet, use the second half the following day.
Supplement Advisor's Note:
The Casperome® delivery technology is genuinely significant — standard Boswellia extracts have poor and variable oral bioavailability, but the phytosome complex substantially improves absorption. This is the mechanism behind why this product outperforms generic Boswellia supplements. For cats specifically, this is one of the few natural anti-inflammatory options that is both feline-safe and has a legitimate registration — making it a meaningful tool when NSAIDs are contraindicated due to kidney concerns, which is common in senior cats.
Q: Will this make my pet sedated or lethargic?
A: No. The hemp component provides phytocannabinoids in compliance with Health Canada regulations and is not intended to produce sedation. Most owners report their pets become more active, not less.
Q: How soon will I see results?
A: Many owners report visible improvement within 2 weeks. Full benefit is typically observed after 4–6 weeks of consistent use.
Q: Is this safe for cats with kidney disease?
A: Because this product avoids NSAIDs entirely, it is a commonly considered option for senior cats where NSAID use is limited by renal concerns. Always confirm with your veterinarian.
Q: Is this registered with Health Canada?
A: Yes, as a Veterinary Health Product (VHP NN. F3T1).
